Discontinuation report LAMISIL
| Report ID | 244096 |
| Drug Identification Number | 02031116 |
| Brand name | LAMISIL |
| Common or Proper name | LAMISIL TAB 250MG 2 X 14 |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | TERBINAFINE |
| Strength(s) | 250MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 2 X 14 |
| ATC code | D01BA |
| ATC description | ANTIFUNGALS FOR SYSTEMIC USE |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2025-03-01 |
| Actual discontinuation date | |
| Remaining supply date | 2025-08-31 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
| Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2024-11-28 | English | Compare |
| v2 | 2024-11-28 | English | Compare |
| v3 | 2024-11-28 | French | Compare |
| v4 | 2024-11-28 | English | Compare |
| v5 | 2024-11-28 | French | Compare |
Showing 1 to 5 of 5